Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Camu Camu in Metastatic Renal Cell Carcinoma
NCT06049576Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of myrciaria dubia in renal cell carcinoma (RCC) (2 arms), sponsored by City of Hope. Primary endpoint: Abundance of ruminococcus in the stool at week 12. Started Oct 2023; status: suspended.
02
Drugs
myrciaria dubia
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06049576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049576.